NeurAxis, Inc.: Fourth Quarter and Fiscal Year 2024 Financial Results and Conference Call
On March 12, 2025, NeurAxis, Inc., a leading medical technology company specializing in neuromodulation therapies for chronic and debilitating conditions in children and adults, announced that it will release summarized financial results for its fourth quarter and fiscal year 2024, which ended on December 31, 2024. The financial report is scheduled to be published before the market open on Thursday, March 20, 2025.
Impact on NeurAxis Shareholders
The release of NeurAxis’ financial results for Q4 and FY 2024 is expected to provide valuable insights into the Company’s financial performance during this period. Shareholders and investors will be closely monitoring the financial report for key metrics such as revenue growth, net income, cash flow, and earnings per share. A strong financial performance could lead to an increase in investor confidence and potentially boost the stock price, while weak results may result in a decline.
Impact on the Neuromodulation Industry
NeurAxis’ financial results for Q4 and FY 2024 are also significant for the neuromodulation industry as a whole. Neuromodulation therapies, which involve the use of electrical impulses to modify the body’s electrical activity, have gained increasing popularity in recent years due to their potential to treat a wide range of chronic and debilitating conditions. NeurAxis’ financial performance could serve as a benchmark for other companies in the industry and provide insights into the overall market trends and growth prospects.
Details of the Conference Call
Following the release of the financial results, NeurAxis has scheduled a conference call for Thursday, March 20, 2025, at 9:00 am ET to review the results in detail. During the call, the Company’s management team will discuss the financial results, provide an update on its business operations, and answer questions from analysts and investors. Interested parties can participate in the conference call by dialing the following numbers:
- US Participants: (877) 407-0784
- International Participants: (201) 689-8560
A live webcast of the conference call will also be available on NeurAxis’ investor relations website. The webcast replay will be accessible for approximately 90 days following the call.
Conclusion
NeurAxis, Inc.’s financial results for Q4 and FY 2024, to be released on March 20, 2025, are of significant interest to both NeurAxis shareholders and the neuromodulation industry as a whole. The financial report and subsequent conference call will provide valuable insights into NeurAxis’ financial performance, business operations, and market trends in the neuromodulation industry. Shareholders and investors will be closely monitoring the results for key metrics and any potential impact on the stock price, while industry observers will look to the report as a benchmark for market trends and growth prospects.
NeurAxis’ financial results and conference call represent an important milestone in the Company’s journey and a significant event for the neuromodulation industry. As the use of neuromodulation therapies continues to grow, companies like NeurAxis will play a crucial role in advancing the field and improving the lives of millions of people suffering from chronic and debilitating conditions. Stay tuned for further updates on this developing story.
